NDA 019452 · Hill Dermac
Derma-Smoothe/Fs
Fluocinolone Acetonide · Topical, Otic · Corticosteroid
Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Feb 3, 1988
Approved uses
7
Original approval plus efficacy supplements
Registered trials
63
20 Phase 3, 7 recruiting
FAERS reports
2,062
880 serious, 48 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2026.
Derma-Smoothe/FS ® Scalp Oil is a corticosteroid indicated for the treatment of psoriasis of the scalp in adults. ( 1 ) DERMA-SMOOTHE/FS ® Scalp Oil is indicated for the treatment of psoriasis of the scalp in adults.
Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in psoriasis of the scalp is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2007 Supplement 24 · Efficacy Label
- Nov 9, 2005 Supplement 20 · Efficacy LetterLabel
- Nov 9, 2005 Supplement 19 · Efficacy LetterLabel
- Oct 10, 2001 Supplement 17 · Efficacy LetterLabelReview
- Aug 18, 1999 Supplement 15 · Efficacy LetterReviewLabel
- Feb 16, 1995 Supplement 10 · Efficacy
- Feb 3, 1988 Original approval · Type 3 - New Dosage Form Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
3 products under this application
- DERMA-SMOOTHE/FS · FLUOCINOLONE ACETONIDE 0.01% · OIL, TOPICAL · Prescription · TE AT
- DERMA-SMOOTHE/FS · FLUOCINOLONE ACETONIDE 0.01% · OIL, TOPICAL · Prescription · TE AT
- DERMOTIC · FLUOCINOLONE ACETONIDE 0.01% · OIL/DROPS, OTIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03568318 · 1,533 participants · Start Aug 9, 2018 · Primary completion Feb 16, 2021
Drug: Placebo; Upadacitinib and 1 more · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 193 sites in all
- Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular EdemaPivotal-lookingCompleted
Alimera SciencesIndustry
NCT00344968 · 956 participants · Start Sep 2007 · Primary completion Dec 2009
Drug: fluocinolone acetonide; Fluocinolone Acetonide · For: Diabetic Macular Edema
Sites: Atlanta, Georgia
- Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02260986 · 740 participants · Start Sep 2014 · Primary completion Aug 2015
Drug: Dupilumab; Placebo (for Dupilumab) · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Little Rock, Arkansas · 148 sites in all
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyPivotal-lookingRecruiting
Jaeb Center for Health ResearchAcademic, hospital or other
NCT05844982 · 600 participants (planned) · Start Nov 21, 2023 · Primary completion Dec 26, 2029
Drug: Faricimab; fluocinolone acetonide · For: Radiation Retinopathy; Visual Impairment
Sites: Palo Alto, California; Manchester, Connecticut; Tampa, Florida · 29 sites in all
- Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis ExternaPivotal-lookingCompleted
Lee's Pharmaceutical LimitedIndustry
NCT04636957 · 600 participants · Start Jan 4, 2021 · Primary completion Oct 17, 2021
Drug: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution; Ciprofloxacin 0.3% solution · For: Acute Otitis Externa
Sites: Shanghai, China
- Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03345914 · 367 participants · Start Nov 17, 2017 · Primary completion Jun 20, 2019
Drug: Dupilumab; Matching Placebo · For: Dermatitis, Atopic
Sites: Birmingham, Alabama; Gilbert, Arizona; Bakersfield, California · 61 sites in all
- A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Alimera SciencesIndustry
NCT04469595 · 300 participants (planned) · Start Aug 31, 2020 · Primary completion Dec 31, 2024
Drug: Iluvien 0.19 MG Drug Implant; Aflibercept · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 40 sites in all
- Safety and Efficacy of Fluocinolone Acetonide Intravitreal ImplantsPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00407082 · 278 participants · Start Dec 2000 · Primary completion Sep 2005
Drug: fluocinolone acetonide intravitreal implant; Fluocinolone acetonide 2.1mg · For: Noninfectious Posterior Uveitis
Sites: Durham, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective209
- pruritus205
- rash165
- diarrhoea129
- psoriasis125
- headache113
- off label use113
- fatigue107
- pain105
- dermatitis atopic93
- nausea93
- dry skin80
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 15 |
| 2006 | 10 |
| 2007 | 12 |
| 2008 | 18 |
| 2009 | 31 |
| 2010 | 20 |
| 2011 | 56 |
| 2012 | 57 |
| 2013 | 25 |
| 2014 | 37 |
| 2015 | 64 |
| 2016 | 87 |
| 2017 | 82 |
| 2018 | 89 |
| 2019 | 125 |
| 2020 | 132 |
| 2021 | 131 |
| 2022 | 175 |
| 2023 | 223 |
| 2024 | 201 |
| 2025 | 248 |
| 2026 | 216 |
Recalls
4 FDA enforcement reports for this application.
May 21, 2021 · Class II · Terminated
Presence of Foreign Substance: Potential for broken glass within the glass pipette of the dropper.
Jan 31, 2014 · Class III · Terminated
Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.
Jan 31, 2014 · Class III · Terminated
Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.
Jan 31, 2014 · Class III · Terminated
Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Derma-Smoothe-FS (Fluocinolone Acetonide)
2024 spending
$6K
Beneficiaries
96
148 claims
Per beneficiary
$68
$0.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,725 |
| 2021 | $12,564 |
| 2022 | $11,580 |
| 2023 | $11,896 |
| 2024 | $6,482 |
Part D: Derma-Smoothe-FS (Fluocinolone/Shower Cap)
2024 spending
$13K
Beneficiaries
243
339 claims
Per beneficiary
$52
$0.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $26,871 |
| 2021 | $20,781 |
| 2022 | $19,664 |
| 2023 | $16,563 |
| 2024 | $12,526 |
Part D: Dermotic (Fluocinolone Acetonide Oil)
2024 spending
$36K
Beneficiaries
1,043
1,316 claims
Per beneficiary
$34
$1.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $28,891 |
| 2021 | $29,530 |
| 2022 | $29,383 |
| 2023 | $32,855 |
| 2024 | $35,968 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Corticosteroid Implants in Non-infectious Uveitis: A Systematic Review with Network Meta-analysis.
Vieira R, Sousa-Pinto B, Figueira L · Ocul Immunol Inflamm 2022 · Systematic Review, Network Meta-Analysis
- Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis.
Liao W, Zhong Z, Su G, et al. · Front Pharmacol 2022 · Systematic Review
- Efficacy and Safety of Fluocinolone Acetonide 0.19 mg Intravitreal Implant for the Treatment of Non-Infectious Uveitis: A Systematic Review of Real-World Evidence.
Christensen LF, Hassing AK, Klefter ON, et al. · Ocul Immunol Inflamm 2025 · Systematic Review
- Interventions for melasma.
Rajaratnam R, Halpern J, Salim A, et al. · Cochrane Database Syst Rev 2010 · Systematic Review
- Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
· Ophthalmology 2015 · Comparative Study, Multicenter Study
- Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Gong Z, Lai W, Zhao G, et al. · Clin Drug Investig 2015 · Multicenter Study, Randomized Controlled Trial
Sponsor: Hill Dermac · Also marketed as Dermotic
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.